As a radiation sensitizer for patients with recurrent or metastatic cancer, the FDA has approved cetuximab, a monoclonal antibody that targets the epidermal growth factor receptor (EGFR; also known as HER1) [2]. The gene discussed is EGFR; the disease is metastatic malignant neoplasm.